EcoDrugPlus

Dna Topoisomerase I

Ensembl ID : ENSPFOG00000008298
Gene Symbol: TOP1
1 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSPFOG00000016534
Gene Symbol: TOP2A
1 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSPFOG00000006761
Gene Symbol: TOP2B
3 Cross references
207 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSPFOG00000001791
Gene Symbol: EML4
4 Cross references
206 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSPFOG00000005536
Gene Symbol: EPHA3
1 Cross references
210 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSPFOG00000020514
Gene Symbol: F2RL3
3 Cross references
195 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSPFOG00000003883
Gene Symbol: FAU
3 Cross references
300 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSPFOG00000002324
Gene Symbol: FYNB
1 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSPFOG00000012818
Gene Symbol: GPR119
2 Cross references
173 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSPFOG00000000496
Gene Symbol: GPR119
2 Cross references
173 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSPFOG00000011000
Gene Symbol: GPR84
1 Cross references
121 Possible Orthologues:

G-Protein Coupled Receptor 84-Like

Ensembl ID : ENSPFOG00000020286
Gene Symbol: LOC103147659
3 Cross references
121 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).